Clinical Experience With Intravenous and Oral Formulations of the Novel Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid in Patients With Advanced Hematologic Malignancies
- 1 January 2006
- journal article
- hematologic malignancies
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 24 (1), 166-173
- https://doi.org/10.1200/jco.2005.01.9679
Abstract
Purpose To document the toxicity and activity of the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in patients with pretreated hematologic malignancies. Patients and Methods Two formulations of SAHA (intravenous [IV] and oral) have been assessed in two consecutive phase I trials. In both trials, dose escalation was performed in parallel and independently in patients with solid tumors and hematologic malignancies. Eligible patients were required to have adequate hepatic and renal function, an absolute neutrophil count ≥ 500/μL and a platelet count more than 25,000/mL. All patients provided informed consent for study inclusion. Results A total of 39 patients with hematologic malignancy were enrolled (14 on IV SAHA and 25 on oral SAHA), of whom 35 were treated. The spectrum of diseases included patients with diffuse large B-cell lymphoma (n = 12), Hodgkin's disease (HD; n = 12), multiple myeloma (n = 2), T-cell lymphoma (n = 3), mantle cell lymphoma (n = 2), small lymphocytic lymphoma (n = 2), and myeloid leukemia (n = 2). Major adverse events with the oral formulation included fatigue, diarrhea, anorexia, and dehydration, whereas myelosuppression and thrombocytopenia were more prominent with the IV formulation. Typically, the hematologic toxicities resolved shortly after SAHA was stopped. There was no neutropenic fever or neutropenic sepsis. Reduction in measurable tumor was observed in five patients. One patient with transformed small lymphocytic lymphoma met criteria for complete response, whereas another met the criteria for partial response (PR). One patient with refractory HD had a PR, whereas three patients had stable disease for up to 9 months. Conclusion These results suggest that SAHA has activity in hematologic malignancies including HD and select subtypes of non-Hodgkin's lymphoma.This publication has 14 references indexed in Scilit:
- Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced CancerJournal of Clinical Oncology, 2005
- Mutations of the BCL6 proto-oncogene disrupt its negative autoregulation in diffuse large B-cell lymphomaBlood, 2003
- Acetylation inactivates the transcriptional repressor BCL6Nature Genetics, 2002
- The human programmed cell death-2 (PDCD2) gene is a target of BCL6 repression: Implications for a role of BCL6 in the down-regulation of apoptosisProceedings of the National Academy of Sciences of the United States of America, 2002
- Histone deacetylases and cancer: causes and therapiesNature Reviews Cancer, 2001
- Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed CellsJNCI Journal of the National Cancer Institute, 2000
- BCL-6 Represses Genes that Function in Lymphocyte Differentiation, Inflammation, and Cell Cycle ControlImmunity, 2000
- Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitorsNature, 1999
- Therapeutic Targeting of Transcription in Acute Promyelocytic Leukemia by Use of an Inhibitor of Histone DeacetylaseJNCI Journal of the National Cancer Institute, 1998
- A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylasesProceedings of the National Academy of Sciences of the United States of America, 1998